

Justification: In FY 2022, under the authority for Special Projects of Regional and National Significance (SPRANS) (42 U.S.C. 701(a)(2) (Title V, § 501(a)(2) of the Social Security Act)), HRSA awarded the ITCP State awards to 12 recipients (HRSA–22–073). This award included expectations for the recipient to continue and expand research-based infant-toddler court (ITC) teams to change child welfare practices and improve the early developmental health and well-being of infants, toddlers, and their families.

A Congressional Report accompanying the Further Consolidated Appropriations Act, 2024 (Pub. L. 118–47), included funding for this program to “continue and expand research-based Infant-Toddler Court Teams to change child welfare practices to improve well-being for infants, toddlers, and their families” (Senate Report 118–84). In addition, the Joint Explanatory Statement accompanying the FY 2024 appropriations act directed HRSA to “allocate funding to ensure continuation of existing grantees, technical assistance, and other activities.” In FY 2024, HRSA provided a supplement of \$2,700,000 in SPRANS funding, through its Maternal and Child Health Bureau, to the ITCP—State Award Program recipients noted in Table 1.¹

A Congressional Report accompanying the FY 2025 appropriations act directed HRSA to “allocate funding to ensure continuation of existing grantees, technical assistance, and support other expansion activities” (House Report 118–585). In response to the Congressional intent, HRSA provided a supplement of \$2,798,847 in SPRANS funding to the

State award recipients in FY 2025 to continue work initiated in prior years, to improve access to evidence-based child welfare practices and improve the early developmental health and well-being of infants, toddlers, and their families.

A Congressional Report accompanying the Consolidated Appropriations Act, 2026 (Pub. L. 119–75) included an additional \$2,000,000, for a total of \$20,000,000 in funding “for research-based Infant-Toddler Court Teams to change child welfare practices to improve well-being for infants, toddlers, and their families” (House Report 119–271). The Report also included a directive to “allocate funding to ensure continuation of existing grantees, technical assistance, and support other expansion activities” (House Report 119–271).

Consistent with Congressional intent, HRSA will provide \$4,588,810 in FY 2026 in supplemental funding to the recipients outlined in Table 1. This supplement will be used to implement project activities within the scope of the current ITCP—State Awards funding opportunity (HRSA–22–073) and to: (1) increase staff capacity through hiring, consultancy, contracting, or training; (2) increase the reach of the infant-toddler court approach by increasing caseloads or expanding to new sites; or (3) address unmet measurement and evaluation needs. These activities are within scope to change child welfare practices to improve well-being for infants, toddlers, and their families.

Margaret M. Bush,
Deputy Administrator.

[FR Doc. 2026–18568 Filed 9–10–26; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Notice of Supplemental Funding, Rural Hospital Stabilization Pilot Program

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services.

ACTION: Notice of supplemental funding.

SUMMARY: HRSA is awarding supplemental funding under the Rural Hospital Stabilization Pilot Program to two award recipients in fiscal year (FY) 2026 to provide in-depth technical assistance (TA) to rural hospitals to enhance and/or expand service lines to meet local needs and keep health care services available locally.

FOR FURTHER INFORMATION CONTACT:

Sheena Johnson, Deputy Division Director, Hospital State Division, Federal Office of Rural Health Policy, HRSA, at sjohnson@hrsa.gov and 872–271–6370.

SUPPLEMENTARY INFORMATION:

Intended Recipient(s) of the Award: two award recipients, as listed in Table 1.

Amount of Non-Competitive Award: two supplemental awards of \$2,984,770.

Project Period: September 30, 2026, to September 29, 2027.

Assistance Listing Number: 93.811.

Award Instrument: Cooperative Agreement.

Authority: Section 711(b)(5) of the Social Security Act.

TABLE 1—RECIPIENT AND AWARD AMOUNT

Grant No.	Award recipient name	City, State	Award amount
U87RH53799	Rural Health Resource Center	Duluth, MN	\$2,984,770
N/A	Rural Health Redesign Center Organization, Inc	Harrisburg, PA	2,984,770

Justification: HRSA received additional funding for the Rural Hospital Stabilization Pilot Program in FY 2026 through the Consolidated Appropriations Act, 2026, (<https://www.congress.gov/119/bills/hr/7148/BILLS-119hr7148enr.pdf>), H.R. 7148. This funding will provide one-time supplements to the Rural Health Resource Center and the Rural Health Redesign Center Organization, Inc to

strengthen healthcare delivery in rural areas by providing free in-depth TA to more rural hospitals nationwide to enhance service lines, improve financial performance, and stabilize operations. The grant recipient will use funding to ramp up operations to identify and work with rural hospitals that will benefit from TA to meet the following program objectives: (1) identify clinical areas where expansion would meet local

medical need, help keep health care services available locally and improve hospital finances, and (2) implement new service lines by providing support for initial operating and equipment costs that provide participating hospitals the ability to build up patient volume for the new service line to

¹ In addition to the recipients included on Table 1, a FY 2024 supplement was provided to the Oklahoma Department of Mental Health and

Substance Abuse Services (Award Number U2ZMC46641). This recipient has since

relinquished their award and will not receive supplemental funds in FY 2026.

eventually become self-sustaining operations.

Thomas J. Engels,
Administrator.

[FR Doc. 2026–18518 Filed 9–10–26; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Sleep Disorders Research Advisory Board (SDRAB).

This will be a virtual meeting and will be open to the public as indicated below. Individuals who plan to view the virtual meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. To register for attending this meeting and it is required to attend, please use the following link: <https://events.gcc.teams.microsoft.com/event/e154949c-695b-4bc5-809f-490cb9277484@14b77578-9773-42d5-8507-251ca2dc2b06?source=copyLink&LegacyShareLinkDialog>.

Name of Committee: Sleep Disorders Research Advisory Board.

Date: December 3, 2026.

Time: 1:00 p.m. to 5:00 p.m.

Agenda: The purpose of this meeting is to seek guidance and gather input from the Sleep Disorders Research Advisory Board on research priorities conducted or supported by the Institute; to update the Advisory Board and public stakeholders on the progress of sleep and circadian research activities across NIH; and to discuss the status of the NIH Sleep Research Plan refresh.

Address: National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Suite 407B, Bethesda, MD 20814.

Meeting Format: Virtual Meeting.

Contact Person: Marishka Brown, Ph.D., SDRAB Executive Secretary, Director, National Center on Sleep Disorders Research, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 407–B, Bethesda 20814–7952, 301–827–7822 ncsdr@nih.gov.

Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be

allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <https://www.nhlbi.nih.gov/about/advisory-and-peer-review-committees/sleep-disorders-research>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center on Sleep Disorders Research; 93.837, Cardiovascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: September 8, 2026.

Denise M. Santeufemio,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–18615 Filed 9–10–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Diabetes and Digestive and Kidney Diseases Advisory Council, October 28, 2026, 08:30 a.m. to October 28, 2026, 03:00 p.m., National Institutes of Health, Building 31, 31 Center Drive, Bethesda, MD, 20892 which was published in the **Federal Register** on July 07, 2026, 91 FR 41646 Doc No. 128.

This notice is being amended to reflect the change in time from 8:30 a.m. to 3:00 p.m. to 10:00 a.m. to 1:00 p.m. The meeting will be open from 10 a.m.–12 p.m. and closed from 12:30 p.m.–1 p.m.

Dated: September 8, 2026.

Rosalind M. Niamke,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–18513 Filed 9–10–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Genes, Genomes, and Genetics Integrated Review Group; Genetic Variation and Evolution Study Section.

Date: October 15–16, 2026.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Michael Patrick O'Connell, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive Bethesda, MD 20892, (301) 867–5309, occonnellmp@mail.nih.gov

Name of Committee: Center for Scientific Review Special Emphasis Panel; Imaging Technology Development Topics.

Date: October 15, 2026.

Time: 9:00 a.m. to 9:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Sue Andersen, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (301) 480–5404, sue.andersen-navalta@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Integrated Approaches in Neurodegeneration.

Date: October 15–16, 2026.

Time: 9:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Bernard Rajeev Srambical Wilfred, Ph.D., Scientific Review Officer, Center for Scientific Review, National